Hypersplenism Clinical Trials

Find Hypersplenism Clinical Trials Near You

Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function in Patients With Hepatocellular Carcinoma and Cirrhotic Hypersplenism: A Prospective Observational Cohort Study

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Splenectomy may relieve hypersplenism, reverse liver fibrosis, improve hepatic functional reserve, and reshape the systemic antitumor immune milieu by removing the source of negative immunomodulation. This prospective cohort study aims to enroll patients undergoing laparoscopic hepatectomy combined with splenectomy for small hepatocellular carcinoma(HCC) with a preoperative platelet count \<80×10\^9/L. The study will evaluate the dynamic changes in hepatic functional reserve, immune function, and risk of HCC recurrence through five post-surgical time points(3, 6, 12, 18, and 24 months after surgery). The endpoints include hepatic functional reserve(ICG-R15, Child-Pugh score, ALBI score, etc.), immune function indicators(peripheral blood lymphocyte subsets: CD4\^+ T cells, CD8\^+ T cells, regulatory T cells, NK cells, etc., and serum cytokine profiles), and HCC recurrence rate within 2 years after surgery(confirmed by imaging). This trial will provide evidence to optimize surgical strategies for patients with small HCC complicated with hypersplenism.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Age 18-80 years, both male and female.

• Hepatocellular carcinoma (HCC) confirmed by clinical, pathological, and radiological examinations, meeting either of the following criteria:Solitary tumor with maximum diameter ≤ 5 cm; or Multiple tumors (≤ 3 in number), each with maximum diameter ≤ 3 cm.

• Liver cirrhosis with splenomegaly and hypersplenism, and preoperative platelet count (Plt) \< 80 × 10⁹/L.

• Liver function Child-Pugh class A or B, with ICG-R15 test indicating tolerance for the planned surgical resection.

• Voluntarily sign written informed consent.

• Able to complete 24-month follow-up.

Locations
Other Locations
China
Clinical Medical College of Yangzhou University
RECRUITING
Yangzhou
Contact Information
Primary
Guo-Qing Jiang, MD
jgqing2003@hotmail.com
+8651487373272
Backup
Dou-Sheng Bai, MD
bdsno1@hotmail.com
Time Frame
Start Date: 2026-08-02
Estimated Completion Date: 2029-10-20
Participants
Target number of participants: 30
Sponsors
Leads: Northern Jiangsu People's Hospital

This content was sourced from clinicaltrials.gov